"Novo Nordisk's Amycretin: A Game-Changer in Weight Loss Treatment"

Novo Nordisk's new weight-loss drug, Amycretin, has shown promising results in an early-stage trial, with participants losing 13.1 percent of their body weight in just 12 weeks. The once-daily pill targets two hormones and has demonstrated a high retention rate and favorable safety profile. While the drug's performance has led to an 8 percent jump in Novo Nordisk shares, further trials and regulatory approval are still needed before it becomes available to patients.